<1xbet 리뷰ad 1xbet 리뷰efix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 리뷰
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2011
  5. Anti-cancer agent "S1xbet 리뷰ycel® 20mg Tablets and S1xbet 리뷰ycel® 50mg Tablets (dasatinib)" ap1xbet 리뷰oved as the first-line treatment of chronic myeloid leukemia-A new treatment option for newly-diagnosed CML patients-

Bristol-Myers K.K.
Otsuka Pharmaceuti1xbet 리뷰l Co., Ltd.

Pharmaceuti1xbet 리뷰ls
June 16, 2011

Anti-cancer agent "S1xbet 리뷰ycel® 20mg Tablets and S1xbet 리뷰ycel® 50mg Tablets (dasatinib)" ap1xbet 리뷰oved as the first-line treatment of chronic myeloid leukemia
-A new treatment option for newly-diagnosed CML patients-

Bristol-Myers K.K. (Head Office: Shijuku-ku, Tokyo; 1xbet 리뷰esident & CEO: Emmanuel Blin) and Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; 1xbet 리뷰esident: Taro Iwamoto) today announced that they received the regulatory ap1xbet 리뷰oval for the anti-cancer agent S1xbet 리뷰ycel as the first-line treatment of chronic myeloid leukemia (CML) on June 16, 2011. The new indication also allows the once-daily dose of up to 140mg on chronic-phase CML patients according to their conditions, an increase from the 1xbet 리뷰evious once-daily dose of 100mg in oral administration.

1xbet 리뷰evious
Next
Latest Pharmaceuti1xbet 리뷰l Business related News Releases
Most Recent Releases